European Society for Medical Oncology

#ESMO #European Society for Medical Oncology #Tumours

New treatment hope for patients with rare tumours

Ayala Pharmaceuticals has revealed positive interim results from its ongoing RINGSIDE Pivotal Phase II and III clinical trial into gamma-secretase inhibitor AL102 in desmoid tumours. The findings were presented at the European Society for Medical Oncology (ESMO) Congress 2022 by Professor Robin Jones, MD, Head of the Sarcoma Unit at… Read More

#News

#Cancer research #Drug discovery #European Society for Medical Oncology #Oncology

This week in drug discovery (5-9 September)

News round-up for 5-9 September by DDW Digital Content Editor Diana Spencer Cancer research has been making headlines over the last seven days in the build-up to the European Society for Medical Oncology (ESMO) Congress 2022. Notably, it was a mixed week for PARP inhibitor olaparib, which was approved by regulator… Read More

#News